



Humana

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG OR SINGAPORE

PRESS RELEASE

05/04/2016

Exercise of the over-allotment option in Humana

The Managers (as defined below) have notified Humana AB ("Humana" or the "Company") and Humana's principal owner, funds advised or managed by Argan Capital Management L.P. ("Argan Capital") that the over-allotment option has been exercised in full in respect of 1,683,029 existing shares in Humana.

- In connection with the initial public offering of Humana, Argan Capital granted the Managers an over-allotment option of up to 1,683,029 existing shares to be used to cover over-allotment of shares and stabilisation of the share price after the listing
- No price stabilisation has been carried out since the listing, and with regards to the Company's share price development, the Managers have decided to exercise the over-allotment option in full and to terminate the stabilisation period
- The exercise of the over-allotment option means that a total of 14,305,750 shares have been sold through the offering, corresponding to approximately 26.9 percent of the total number of shares outstanding in Humana
- Following the exercise of the over-allotment option, Argan Capital holds 29,606,290 shares in Humana, corresponding to approximately 55.7 percent of the total number of shares and votes in Humana

Advisers

In connection to the listing, Carnegie and SEB were acting as Joint Global Coordinators and Joint Bookrunners, and ABG Sundal Collier and DNB were acting as Joint Bookrunners (collectively, the "Managers"). Mannheimer Swartling was legal adviser to Humana and Argan Capital and Gernandt & Danielsson was legal adviser to the Joint Global Coordinators and Joint Bookrunners.

For further information, please contact:

Cecilia Lannebo, Head of Investor Relations, 072-220 82 77, cecilia.lannebo@humana.se

The information is such that Humana AB (publ) is required to disclose in accordance with the Swedish Financial Instruments Trading Act and/or the Swedish Securities Market Act. The information was submitted for publication at 08.00 CET on April 5, 2016.



Humana

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG OR SINGAPORE

About Humana

Humana is a leading Nordic care company with over 14,000 full and part time employees which offers services within individual and family care, personal assistance, elderly care and housing with special service according to LSS. Humana has since 2001 developed from being a niche company within personal assistance, to become a care company offering a broad range of high-quality care services. In Sweden, Humana is the market leader within both individual and family care as well as personal assistance. In Norway, Humana is the second largest provider of services within individual and family care.

Humana's goal is to improve the quality of day-to-day life for all the Company's customers and clients. Operationally, Humana puts great focus and emphasis on quality and customer satisfaction based on the Company's core values and vision. Humana strives to be a reliable and responsible employer and a long-term partner with a large commitment to society, continuously working to drive improvement in the care industry.

Since 2009, the Company's revenue has grown by a compound annual growth rate of 22 percent, driven by both organic initiatives and a large number of acquisitions. Humana's strategy is to focus on operations in segments that are characterized by free customer choice and operations in full-responsibility homes. In 2015 Humana's net revenue amounted to SEK 5,593 million and EBIT amounted to SEK 312 million.

Important information

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Humana in any jurisdiction where such offer or sale would be unlawful.

In EEA Member States, other than Sweden, that have implemented Directive 2003/71/EC as amended (together with any applicable implementing measures, the "Prospectus Directive"), such an offering may be made only in accordance with an exception in the Prospectus Directive or to qualified investors in that Member State within the meaning of the Prospectus Directive.

This document and the information contained herein are not for distribution in or into the United States of America. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.



Humana

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG OR SINGAPORE

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

A prospectus prepared in accordance with the Prospectus Directive has been published and is held available on Humana's website (www.humana.se), Carnegie's website for ongoing offerings (www.carnegie.se/om-carnegie/kontakt/pagaende-erbjudanden), SEB's website for prospectuses (www.sebgroup.com/prospectuses) and Avanza's website (www.avanza.se).

This document constitutes advertisement and is not a prospectus for the purposes of the Prospectus Directive. Investors may not acquire any securities referred to in this press release except on the basis of information contained in the prospectus.

Matters discussed in this release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe," "expect," "anticipate," "intends," "estimate," "will," "may," "continue," "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this release speak only as at its date, and are subject to change without notice.